Patents by Inventor Ethan SOKOL

Ethan SOKOL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230416831
    Abstract: The present disclosure relates to methods of treating or delaying progression of invasive lobular carcinoma (ILC) metastasis in an individual, methods for evaluating, identifying, and/or assessing an individual having an ILC metastasis, as well as methods for genomic profiling of an ILC metastasis.
    Type: Application
    Filed: December 6, 2021
    Publication date: December 28, 2023
    Applicant: Foundation Medicine, Inc.
    Inventor: Ethan SOKOL
  • Publication number: 20230140123
    Abstract: Described herein are methods, devices, and systems for identifying a subset of a plurality of features, using one or more feature importance metrics, for training and using a homologous repair deficiency (HRD) classification model. Further described are methods, devices, and systems for classifying a tumor of a cancer, such as pancreatic cancer, as likely HRD positive or likely HRD negative, and for calling the tumor as HRD positive or HRD negative.
    Type: Application
    Filed: August 30, 2022
    Publication date: May 4, 2023
    Applicant: Foundation Medicine, Inc.
    Inventors: Ethan SOKOL, Jay MOORE, Justin NEWBERG, Dexter JIN, Kuei-Ting CHEN, Russell MADISON
  • Publication number: 20220396839
    Abstract: Provided herein are methods for detecting a Ewing sarcoma breakpoint region 1 (EWSR1) fusion gene encoding a neoantigen (e.g., in a patient sample), as well as methods of prognosis and treatment related thereto, in some embodiments, the methods further comprise administering a cancer immunotherapy. In some embodiments, the EWSR1 fusion gene is a fusion gene between EWSR1 and WT1, Fill, ERG, FEV, NR4A3, ATF1, CREB1, CREM, CREB3L/CREB3L2, PA7Z1, NFATC2, KLFI5, C11orf93, ZNF444, PBX1, DDIT3, or TFCP2 that encodes a neoantigen.
    Type: Application
    Filed: November 10, 2020
    Publication date: December 15, 2022
    Applicant: Foundation Medicine, Inc.
    Inventors: Dexter X. JIN, Ethan SOKOL, Sally TRABUCCO, Dean PAVLICK, Siraj ALI
  • Publication number: 20170267970
    Abstract: The presently disclosed subject matter provides hydrogel precursor compositions (e.g., solutions) for forming three-dimensional hydrogels that support growth of physiologically relevant tissue when at least one cell is cultured in the three-dimensional hydrogel, kits comprising the hydrogel precursor composition, three-dimensional hydrogels, methods of forming the three-dimensional hydrogels, methods of growing the physiologically relevant tissue using the three-dimensional hydrogels, physiologically relevant tissue grown in the three-dimensional hydrogels, methods of producing hormone-responsive tissue (e.g., milk-producing mammary tissue and related methods of producing milk), methods of screening for candidate agents useful for modulating hormonal responses (e.g., modulating milk production), method of screening for candidate therapeutic agents using the physiologically relevant tissue grown in the three-dimensional hydrogels (e.g., personalized cancer treatments), and related methods of treatment (e.g.
    Type: Application
    Filed: February 28, 2017
    Publication date: September 21, 2017
    Applicant: Whitehead Institute for Biomedical Research
    Inventors: Piyush GUPTA, Daniel MILLER, Ethan SOKOL